How much benefit can be expected from matching for minor antigens in allogeneic marrow transplantation?

Bone Marrow Transplantation

Volumn 20, Issue 2, 1997, Pages 97-100

  Martin, P J ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Graft versus host disease; Marrow transplantation; Minor histocompatibility antigens

Indexed keywords

MINOR HISTOCOMPATIBILITY ANTIGEN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; GENE LOCUS; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY GENE; HLA MATCHING; HLA TYPING; HUMAN; HUMAN CELL; MODEL; PRIORITY JOURNAL; SIBLING;

EID: 0030848118     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700868     Document Type: Article

References (5)

1. Perreault C, Decary F, Brochu S et al. Minor histocompatibility antigens. Blood 1990; 76: 1269-1280.
2. Goulmy E, Schipper R, Pool J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. New Engl J Med 1996; 334: 281-285.
3. Martin PJ. Increased disparity for minor histocompatibility antigens as a potential cause of increased GVHD risk in marrow transplantation from unrelated donors compared with related donors. Bone Marrow Transplant 1991; 8: 217-223.
4. Beatty PG, Hansen JA, Longton G et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 51: 443-447.
5. Storb R, Prentice RL, Hansen JA, Thomas ED. Association between HLA-B antisens and acute graft-versus-host disease. Lancet 1983; II: 816-819.